Business
MediWound Announces Commercial Launch of NexoBrid® in Japan
Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement YAVNE, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd.
About this update from Mediwound Ltd.
[{"type":"text","content":"Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement\nYAVNE, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that its strategic partner, Kaken Pharmaceutical Co. Ltd, launched NexoBrid® in Japan for the treatment of deep partial thickness and full thickness burns in adults and pediatric patients. Kaken Pharmaceutical, a top ranked Japanese pharmaceutical company, has the exclusive marketing and distribution rights for NexoBrid in Japan. NexoBrid is indicated for the removal of eschar in deep partial and full thickness thermal burns. The current standard of care is primarily based on non-selective, expensive, and potentially disfiguring surgical excisions. NexoBrid offers burn specialists with an alternative of a single 4-hour topical treatment, after which the dissolved eschar is removed, leaving a clean wound bed ready for healing. “As one of the top healthcare markets worldwide, Japan holds special strategic importance. Over 6,000 patients are treated for severe burns in Japan every year, with a majority of these patients undergoing eschar removal as a critical first step. NexoBrid can now be a non-surgical treatment option for these patients,” stated Ofer Gonen, Chief Executive Officer of MediWound. “We are proud to have Kaken Pharmaceutical, a trusted and valuable partner, leading the commercialization of NexoBrid in this key market. Kaken Pharmaceutical is a major drug manufacturer in Japan with a unique core marketing competency for both drugs and medical devices, which is critical in promoting a product like NexoBrid.” Hiroyuki Horiuchi, President and Representative Director of Kaken Pharmaceutical stated, “We are excited to introduce this drug to the Japanese market. The prospects are excellent for it becoming the new standard-of-care for serious and life-threatening burns, bringing significant benefits to providers and patients alike. Given our long-term relationship with MediWound, we have been anticipating this moment. Our experience selling products in the burn treatment area along with our existing relationships in the hospital systems prepares us to transform NexoBrid into the standard of care for severe burns.” About Nex...